最近搜索:細胞培養(yǎng) 微生物學(xué) 分子生物 生物化學(xué)
    首頁>>免疫學(xué)>>一抗>>磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
    磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
    • 產(chǎn)品貨號:
      BN42097R
    • 中文名稱:
      磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
    • 英文名稱:
      Rabbit anti-phospho-JAK2 (Tyr1007+Tyr1008) Monoclonal antibody
    • 品牌:
      Biorigin
    • 貨號

      產(chǎn)品規(guī)格

      售價

      備注

    • BN42097R-50ul

      50ul

      ¥2020.00

      交叉反應(yīng):Human,Mouse,Rat(predicted:Chicken,Pig,Rabbit) 推薦應(yīng)用:IHC-P,IHC-F,ICC,IF

    • BN42097R-100ul

      100ul

      ¥3240.00

      交叉反應(yīng):Human,Mouse,Rat(predicted:Chicken,Pig,Rabbit) 推薦應(yīng)用:IHC-P,IHC-F,ICC,IF

    產(chǎn)品描述

    英文名稱phospho-JAK2 (Tyr1007+Tyr1008)
    中文名稱磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
    別    名JAK2(Y1007+Y1008); JAK2 (phospho Y1007); p-JAK2 (phospho Y1007); JAK2 (phospho Y1007 + Y1008); p-JAK2 (phospho Y1007 + Y1008); JAK2(Phospho-Tyr1007/1008); Tyrosine protein kinase JAK2; JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating Kinase 2; Janus Kinase 2; JTK 10; JTK10; OTTHUMP00000043260; Tyrosine-protein kinase JAK2; Tyrosine protein kinase JAK2.  
    產(chǎn)品類型磷酸化抗體 
    研究領(lǐng)域腫瘤  細胞生物  染色質(zhì)和核信號  信號轉(zhuǎn)導(dǎo)  激酶和磷酸酶  表觀遺傳學(xué)  
    抗體來源Rabbit
    克隆類型Monoclonal
    克 隆 號6E5
    交叉反應(yīng)Human, Mouse, Rat,  (predicted: Chicken, Pig, Rabbit, )
    產(chǎn)品應(yīng)用IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50 IF=1:50-200 (石蠟切片需做抗原修復(fù))
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    分 子 量131kDa
    細胞定位細胞核 細胞漿 細胞膜 
    性    狀Liquid
    濃    度1mg/ml
    免 疫 原KLH conjugated Synthesised phosphopeptide derived from human JAK2 around the phosphorylation site of Tyr1007/1008:KE(p-Y)(p-Y)KV 
    亞    型IgG
    純化方法affinity purified by Protein A
    儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
    PubMedPubMed
    產(chǎn)品介紹JAK2 (Janus Activating Kinase 2) is a tyrosine kinase of the non-receptor type, that associates with the intracellular domains of cytokine receptors; JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin; it has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Ligand binding to a variety of cell surface receptors (e.g., cytokine, growth factor, GPCRs) leads to an association of those receptors with JAK proteins, which are then activated via phosphorylation on tyrosines 1007 and 1008 in the kinase activation loop. Activated JAK proteins phosphorylate and activate STAT (signal transducers and activators of transcription) proteins, which then dimerize and translocate to the nucleus. Once in the nucleus, STAT proteins bind to DNA and modify the transcription of various genes.

    Function:
    Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.

    Subunit:
    Interacts with EPOR, LYN, SIRPA, SH2B1 and TEC. Interacts with IL23R, SKB1 and STAM2.

    Subcellular Location:
    Endomembrane system; Peripheral membrane protein. Cytoplasm. Nucleus.

    Tissue Specificity:
    Ubiquitously expressed throughout most tissues.

    Post-translational modifications:
    Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. Also phosphorylated by TEC.

    DISEASE:
    Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
    Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:600880]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.

    Similarity:
    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.

    SWISS:
    O60674

    Gene ID:
    3717

    Database links:

    Entrez Gene: 3717 Human

    Entrez Gene: 16452 Mouse

    Entrez Gene: 24514 Rat

    GenBank: NP_004963 Human

    Omim: 147796 Human

    SwissProt: O60674 Human

    SwissProt: Q62120 Mouse

    SwissProt: Q62689 Rat

    Unigene: 656213 Human

    Unigene: 275839 Mouse

    Unigene: 18909 Rat



    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications


    亚洲性色AV日韩在线观看| 人人狠狠综合久久亚洲高清 | 高清在线亚洲精品国产二区| 亚洲字幕AV一区二区三区四区| 亚洲不卡视频在线观看| 久久精品国产亚洲沈樵| 亚洲人成网7777777国产| 综合亚洲伊人午夜网| 中文字幕精品亚洲无线码一区| 国产a v无码专区亚洲av| 亚洲一区精品伊人久久伊人| 国产成人精品日本亚洲专区| 亚洲中文字幕无码专区| 亚洲免费日韩无码系列| 毛茸茸bbw亚洲人| 亚洲精品乱码久久久久久按摩 | 亚洲性69影院在线观看| 亚洲国产视频一区| 亚洲mv国产精品mv日本mv| 亚洲中文字幕无码一去台湾 | 国产亚洲精品精品国产亚洲综合| 久久久久亚洲AV成人网人人网站| 久久亚洲国产精品五月天婷| 亚洲真人无码永久在线| 亚洲老妈激情一区二区三区| 亚洲av永久无码精品国产精品| 亚洲AV区无码字幕中文色 | 激情小说亚洲图片| 国产a v无码专区亚洲av| 亚洲综合日韩久久成人AV| 亚洲国产精品高清久久久| 久久亚洲AV成人出白浆无码国产| 亚洲日本香蕉视频| 在线aⅴ亚洲中文字幕| 337P日本欧洲亚洲大胆精品| 亚洲日本中文字幕一区二区三区| 亚洲精品国精品久久99热一| 亚洲一区二区三区电影| 亚洲免费在线视频播放| 亚洲国产午夜精品理论片在线播放| 全亚洲最新黄色特级网站 |